Regulus Therapeutics (RGLS) Stock Price, News & Analysis

Company Overview

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $8.16 to $8.16
• 50-Day Range: $7.87 to $8.30
• 52-Week Range: $0.83 to $8.35
• Volume: N/A
• Average Volume: 1.02 million shs
• Market Capitalization: $564.92 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.80
• Consensus Rating: Hold

RGLS Stock Analysis - Frequently Asked Questions

How were Regulus Therapeutics' earnings last quarter?

Regulus Therapeutics Inc. (NASDAQ:RGLS) released its quarterly earnings data on Thursday, May, 8th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29) by $0.14.

When did Regulus Therapeutics' stock split?

Shares of Regulus Therapeutics reverse split on the morning of Wednesday, June 29th 2022.The 1-10 reverse split was announced on Wednesday, June 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Regulus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Regulus Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), ServiceNow (NOW) and Eli Lilly and Company (LLY).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 8/16/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:RGLS
• CIK: 1505512
• Web: www.regulusrx.com
• Phone: (858) 202-6300
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Regulus Therapeutics: $8.80
• High Price Target: $11.00
• Low Price Target: $7.00
• Potential Upside/Downside: +7.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.17
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.73)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$46.36 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -57.53%
• Return on Assets: -53.26%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 16.31
• Quick Ratio: 16.31

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.17 per share
• Price / Book: 6.97

Miscellaneous

• Outstanding Shares: 69,230,000
• Free Float: 66,222,000
• Market Cap: $564.92 million
• Optionable: Optionable
• Beta: 0.35